The evolving role of biologics in the treatment of pediatric psoriasis.

This article will provide a summary of the cumulative pediatric safety and efficacy data for the anti-tumor necrosis factor-alpha (TNF-α) agents and interleukin (IL)-12 and IL-23 (IL12/23) pathway inhibitor and suggestions for a rational clinical approach to their use in children with psoriasis. PMID: 23508772 [PubMed - in process]
Source: Skin Therapy Letter - Category: Dermatology Authors: Tags: Skin Therapy Lett Source Type: research

Related Links:

Condition:   Coronavirus Infection Intervention:   Diagnostic Test: Nasopharyngeal swab Sponsors:   Universita di Verona;   Azienda Ospedaliera Universitaria Integrata Verona Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Many people think of hair loss as a male problem, but it also affects at least a third of women. But unlike men, women typically experience thinning hair without going bald, and there can be a number of different underlying causes for the problem. “Some are associated with inflammation in the body. Some are female-pattern hair loss,” says Dr. Deborah Scott, assistant professor of dermatology at Harvard Medical School and co-director of the Hair Loss Clinic at Brigham and Women’s Hospital. But the good news is that in many cases this hair loss can be stabilized with treatment, and it may be reversible. Whe...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Health Skin and Hair Care Women's Health Source Type: blogs
CONCLUSION: Only a shared management of the psoriatic patient can allow for the best treatment and follow-up of these patients, a more rational use of available medical resources, thus giving the patient the best possible quality of life. PMID: 32208131 [PubMed - as supplied by publisher]
Source: Acta Medica Portuguesa - Category: General Medicine Tags: Acta Med Port Source Type: research
Authors: Đorđević Betetto L, Žgavec B, Bergant Suhodolčan A Abstract Tinea incognita is an atypical presentation of fungal infection of the skin, the clinical presentation of which has been modified by misuse of topical corticosteroids or calcineurin inhibitors. Such dermatophyte infections often have an atypical clinical presentation and are difficult to diagnose, but with the rise of immunosuppressive drugs and self-prescribed topical therapies, they are becoming increasingly prevalent. Here we report the case of a 68-year-old male patient with a history of psoriasis, presenting with erythematous scaly lesio...
Source: Acta Dermatovenerologica Alpina, Panonica, et Adriatica - Category: Dermatology Tags: Acta Dermatovenerol Alp Pannonica Adriat Source Type: research
Publication date: Available online 24 March 2020Source: International Journal of PharmaceuticsAuthor(s): Ahmed Alalaiwe, Chwan-Fwu Lin, Chien-Yu Hsiao, En-Li Chen, Chien-Yu Lin, Wan-Chen Lien, Jia-You Fang
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research
Source: Journal of the American Academy of Dermatology - Category: Dermatology Authors: Source Type: research
In conclusion, our findings suggest a potential role for mononuclear phagocytes in the pathogenesis of psoriasis.
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
AbstractPurposeIL-23 is a central proinflammatory cytokine with a wide range of influence over immune response. It is implicated in several autoimmune diseases due to the infinite inflammatory loops it can create through the positive feedbacks of both IL-17 and IL-22 arms. This made IL-23 a key target of autoimmune disorders therapy, which indeed was proven to inhibit inflammation and ameliorate diseases. Current autoimmune treatments targeting IL-23 are either by preventing IL-23 ligation to its receptor (IL-23R) via antibodies or inhibiting IL-23 signaling by signaling downstream mediators ’ inhibitors, with each a...
Source: Inflammation Research - Category: Research Source Type: research
Conclusion: Absolute PASI appeared to be a feasible alternative to PASI response for determining treatment success, reflecting HrQoL improvements in an equal manner. PMID: 32202943 [PubMed - as supplied by publisher]
Source: Journal of Dermatological Treatment - Category: Dermatology Tags: J Dermatolog Treat Source Type: research
Conclusions: This NMA demonstrated that evaluated IL-17 and IL-23 inhibitors outperformed other biological therapies after one year. Risankizumab had a higher probability of achieving PASI outcomes than all other biologics, except brodalumab and guselkumab, where no significant difference could be concluded. PMID: 32202445 [PubMed - as supplied by publisher]
Source: Journal of Dermatological Treatment - Category: Dermatology Tags: J Dermatolog Treat Source Type: research
More News: Children | Dermatology | Laboratory Medicine | Pediatrics | Psoriasis | Skin | Toxicology